Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Background Persons with toxic gain-of-function variants in the gene encoding
apolipoprotein L1 (APOL1) are at greater risk for the development of rapidly progressive …

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite
use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often …

Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …

Loss of normal kidney function affects more than 10% of the population and contributes to
morbidity and mortality. Kidney diseases are currently treated with immunosuppressive …

Background Reductions in albuminuria are associated with a subsequent lower risk of
kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin …

Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the
availability of pharmacological treatments, both diseases remain associated with …